Clinical Trials

25 enrolled

Pancreatic Ductal Adenocarcinoma

NCT05239741 2026-03-10

MK-3475-C66

100 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT06346392 2026-03-09

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

572 enrolled

Stomach Neoplasms

NCT06951503 2026-03-04

AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer

560 enrolled

Colorectal Adenocarcinoma

NCT05365581 2026-02-13

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

398 enrolled

Tumor-Agnostic

Adenocarcinoma

NCT06219941 2026-02-12

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

Phase 2 Recruiting

224 enrolled

Biliary Tract Neoplasms, Stomach Neoplasms

NCT04342910 2026-01-20

Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC

550 enrolled

Stomach Neoplasms

NCT06792695 2026-01-20

CANTOR

Phase 2 Recruiting

120 enrolled

Neoplasm Metastasis, Colorectal Neoplasms

NCT07056777 2026-01-13

Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer

Phase 1/2 Recruiting

186 enrolled

Gastrointestinal Neoplasms

NCT06644781 2026-01-12

A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

510 enrolled

Esophageal Squamous Cell Carcinoma

NCT06586515 2025-12-22

MOONRAY-01

630 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT06769425 2025-06-24

HS-10502

BreastGastrointestinalGenitourinaryGynecologic

157 enrolled

Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

NCT06954246 2025-06-18

A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

450 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT04415853 2025-05-18

Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer

416 enrolled

Esophageal Neoplasms

NCT05978492 2025-04-24

A Study of TXN10128 in Subjects With Solid Tumors

96 enrolled

Other solid neoplasm

Locally Advanced (Unresectable) or Metastatic Solid Tumors

NCT05859750 2024-12-16

A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer

Phase 2 Recruiting

78 enrolled

Pancreatic Neoplasms

NCT06496048 2024-12-12

Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC

180 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT06194734 2024-03-07

A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer

490 enrolled

Esophageal Squamous Cell Carcinoma

NCT06123494 2024-01-16

SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen

360 enrolled

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

NCT05427383 2023-12-19

KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy

Phase 2/3 Recruiting

286 enrolled